Sort   by:  
 Page size 
UnknownLong-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Not available
S-EPMC6619057 | biostudies-literature
UnknownPost-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Not available
S-EPMC7905790 | biostudies-literature
UnknownConsistent improvement with eculizumab across muscle groups in myasthenia gravis.
Not available
S-EPMC7448154 | biostudies-literature
UnknownEculizumab improves fatigue in refractory generalized myasthenia gravis.
Not available
S-EPMC6620379 | biostudies-literature
Unknown'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Not available
S-EPMC7320935 | biostudies-literature
UnknownDefining the role of common variation in the genomic and biological architecture of adult human height.
Not available
S-EPMC4250049 | biostudies-literature
UnknownGeoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies.
Not available
S-EPMC8766316 | biostudies-literature
UnknownClinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
Not available
S-EPMC10346130 | biostudies-literature
UnknownSARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Not available
S-EPMC11117088 | biostudies-literature
UnknownRisk of COVID-19 after natural infection or vaccination.
Not available
S-EPMC10518569 | biostudies-literature
Sort   by:  
 Page size